MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 68.36% | -14.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.37% | -8.70% | |||
| Operating Income | -7.37% | 8.70% | |||
| Income Before Tax | -10.06% | 11.06% | |||
| Income Tax Expenses | 150.81% | 115.65% | |||
| Earnings from Continuing Operations | -10.61% | 10.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -38.76% | |||
| Net Income | -11.66% | 10.47% | |||
| EBIT | -7.37% | 8.70% | |||
| EBITDA | -7.31% | 8.80% | |||
| EPS Basic | -6.48% | 16.52% | |||
| Normalized Basic EPS | -6.56% | 16.51% | |||
| EPS Diluted | -6.48% | 16.52% | |||
| Normalized Diluted EPS | -6.56% | 16.51% | |||
| Average Basic Shares Outstanding | 4.86% | 7.26% | |||
| Average Diluted Shares Outstanding | 4.86% | 7.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||